Justin S. Waters - Concepedia

Author

Justin S. Waters

Also Known As

Ashwin Verma, I N Steen, J S Waters, J Waters, J. S. Waters, J. Waters, J.S. Waters, Jane S. Waters, Justin S Waters, Justin S. Waters

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Maidstone Hospital Royal Marsden Hospital Royal Marsden NHS Foundation Trust Weston Park Cancer Centre University College London

About

Justin S. Waters is an author at Maidstone Hospital specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	2.1K
2	Health Sciences	3	3	562
3	Education	1	1	450
4	Natural Sciences	1	1	450
5	Public Health	1	1	128

Justin S. Waters

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Ian Chau, David Cunningham, David González, The Lancet Oncology OncologyOpen-label Phase 3Cancer ManagementPathologyCancer Treatment	2013	723
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, The Lancet Oncology	2021	711
Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data Ian Chau, Andy Norman, David Cunningham, Journal of Clinical Oncology	2004	527
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Paul J. Ross, S. Ashley, A. Norton, British Journal of Cancer	2004	470
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma Justin S. Waters, Andrew Webb, David Cunningham, Journal of Clinical Oncology	2000	455
The dynamics of animal social networks: analytical, conceptual, and theoretical advances Noa Pinter‐Wollman, E. A. Hobson, Jennifer E. Smith, Behavioral Ecology Interaction NetworkNetwork AnalysisEducationSocial NetworkNetwork Evolution	2013	450
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer Anthony Maraveyas, Justin S. Waters, Rajarshi Roy, European Journal of Cancer Pancreatic CancerMedicineGemcitabine Versus GemcitabinePharmacotherapyOncology	2011	314
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Justin S. Waters, A. Norman, David Cunningham, British Journal of Cancer	1999	278
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial Juan W. Valle, Harpreet Wasan, Andre Lopes, The Lancet Oncology Surgical OncologyGastrointestinal OncologyMedicineBiliary CancerRandomised Phase 2	2015	276
ABC-06 \| A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Journal of Clinical Oncology Cancer ManagementPrognosisPathologyLiver FunctionRobust Evidence	2019	226

Page 1